🇺🇸 FDA
Company

KalVista

KalVista Pharmaceuticals

KALV pharma USA

Quick answer

KalVista is a pharma company (KALV) headquartered in FRAMINGHAM, MA, USA with 8 tracked pipeline programs.

Pipeline (8)

project

KVD900 150 mg

Hereditary Angioedema

Phase 3 · small_molecule · completed

1 trials project

KVD900 600 mg

Hereditary Angioedema

Phase 3 · small_molecule · active

2 trials project

Placebo

Hereditary Angioedema

Phase 3 · small_molecule · completed

1 trials project

KVD001 Injection

Diabetic Macular Edema

Phase 2 · small_molecule · completed

2 trials project

KVD824

Angioedema, Hereditary, Types I and II

Phase 2 · small_molecule · terminated

1 trials project

KVD900

Hereditary Angioedema

Phase 2 · small_molecule · completed

2 trials project

KVD824

Hereditary Angioedema

Phase 1 · small_molecule · completed

1 trials project

KVD824 Prototype 1 modified-release tablet

Hereditary Angioedema

Phase 1 · small_molecule · completed

1 trials

Drugs (1)

drug

sebetralstat

EKTERLY

Patents (8)

patent

US 11739068

Polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4

Expires Mon Aug 24 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11613527

Enzyme inhibitors

Expires Mon Mar 23 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11584735

Solid forms of a plasma kallikrein inhibitor and salts thereof

Expires Mon Feb 16 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11242333

Inhibitors of plasma kallikrein

Expires Mon Feb 03 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11234939

Dosage forms comprising a plasma kallikrein inhibitor

Expires Mon Jan 27 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11230537

Polymorphs of n-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3-(methoxymethyl)-1-({4

Expires Mon Jan 20 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11198691

N-((het)arylmethyl)-heteroaryl-carboxamides compounds as kallikrein inhibitors

Expires Mon Dec 09 2041 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11180484

Pyrazole derivatives as plasma kallikrein inhibitors

Expires Mon Nov 18 2041 00:00:00 GMT+0000 (Coordinated Universal Time)